Last updated: July 16, 2026
Executive summary
The docket entry provided identifies a pending case in the Southern District of Florida (civil action number 2:25-cv-15027) captioned Actelion Pharmaceuticals Ltd v. Seasons Biotechnology (Taizhou) Co. Ltd. No further record-level details (asserted patents, venue-specific filings, ANDA/BLA posture, claim charts, motions, orders, or settlement terms) are included in the input. Without those docket specifics, a complete litigation summary and infringement/exclusivity analysis cannot be produced.
What litigation is Actelion Pharmaceuticals bringing against Seasons Biotechnology (Taizhou) in 2:25-cv-15027?
No actionable litigation facts are present beyond the case caption and civil action number. A litigation summary requires, at minimum, the asserted patent list (including patent numbers), the statutory basis (Hatch-Waxman Paragraph IV vs. other), the FDA product link (ANDA/BLA number), and the procedural posture (complaint, motion to dismiss, claim construction, preliminary injunction, stay).
What is the case procedural posture for 2:25-cv-15027?
Not specified in the provided input. Procedural posture determines whether the dispute is at the pleadings stage, claim construction, summary judgment, or trial.
What claims and remedies are typically sought in Actelion patent suits?
The input provides no record-level indication of requested remedies (e.g., injunctive relief, declaratory judgment, attorney fees, damages, or enhanced damages), so a remedies-focused analysis cannot be completed.
What patents are asserted in Actelion v. Seasons Biotechnology (Taizhou) (2:25-cv-15027)?
No patent numbers or families are included in the input. A patent-portfolio analysis requires the exact asserted claims/patents and the asserted product configuration.
How many patents are asserted and what patent types are likely in play?
Not derivable from the input. In Actelion matters, asserted estates often span composition, formulation, method-of-use, and manufacturing, but no asserted-type mapping can be made without the complaint or docket attachments.
Are method-of-use, formulation, or manufacturing claims asserted?
Not specified. Without the complaint’s claim chart references or the infringement allegations, this cannot be answered.
Is this a Paragraph IV Hatch-Waxman case, and what does that imply for timing?
The input does not specify whether the case is tied to an ANDA with a Paragraph IV certification or to a BLA/biosimilar pathway.
When does FDA exclusivity or patent expiry matter for 2:25-cv-15027?
Not specified. Timelines depend on:
- the reference listed drug (RLD) and application type,
- patent expiry dates (including pediatric exclusivity),
- any 180-day exclusivity status,
- whether the action is stayed under 21 U.S.C. § 355(j)(5)(B) or proceeds.
What did Actelion argue on key motion practice in 2:25-cv-15027?
No motion history is included in the input. A litigation analysis requires at least:
- motion to dismiss grounds (standing, failure to state, noninfringement, invalidity),
- preliminary injunction briefing (likelihood of success, irreparable harm),
- claim construction orders (Markman),
- summary judgment outcomes.
What invalidity arguments are usually raised in these cases?
Not available from the input. Invalidity analysis is claim-dependent and requires the asserted patents and defendants’ positions.
What settlement terms or stipulations exist for Actelion v. Seasons Biotechnology (Taizhou)?
No settlement, consent judgment, or dismissal/stipulation details are provided. Settlement analysis requires docket entries, filed agreements, or court orders.
Did the parties enter a consent decree or narrow injunction?
Not specified.
How does the drug and Orange Book status drive the risk profile in this case?
The input does not identify the target product. Without:
- the RLD name,
- Orange Book listed patents,
- the application number,
- and the certified patents,
there is no basis for Orange Book status analysis or generic entry risk mapping.
What is the Orange Book listing status of the asserted patents?
Not provided.
What generic launch risks exist if Actelion’s claims fail?
Not provided. Launch timing depends on FDA approval status, exclusivity protections, and whether any court stay applies.
Which companies are involved besides Actelion and Seasons Biotechnology (Taizhou)?
No other parties are included in the input. Litigation risk and claim scope can hinge on whether co-defendants include distributors, manufacturers, or affiliates.
Key information needed to make a correct infringement and invalidity analysis
None of the required record facts are present in the input, so a correct analysis is not possible:
- asserted patent numbers and claim(s)
- accused product and dosage form
- ANDA/BLA number and certification(s)
- any claim construction positions
- court orders on motions
- trial dates or scheduling order
- settlement or stipulations
Key Takeaways
- The provided information identifies only the case caption and docket number: Actelion Pharmaceuticals Ltd v. Seasons Biotechnology (Taizhou) Co. Ltd., No. 2:25-cv-15027.
- A substantive litigation summary and patent/IP analysis cannot be completed without docket record details on asserted patents, FDA application posture, and procedural milestones.
- Any claims about Paragraph IV status, Orange Book listings, exclusivity timelines, or settlement outcomes would require citations to specific filings and orders, which are not present in the input.
FAQs
- What is the asserted RLD (reference listed drug) in Actelion v. Seasons Biotechnology (Taizhou) 2:25-cv-15027?
- Are the asserted patents composition, formulation, method-of-use, or manufacturing in 2:25-cv-15027?
- Does 2:25-cv-15027 include a Paragraph IV certification tied to an ANDA, and what is the ANDA number?
- What dispositive rulings or claim construction orders exist so far in 2:25-cv-15027?
- Has the case settled or been voluntarily dismissed, and what is the effective date?
References
- None provided.
